Value
3.2/10data confidence 67%| Component | Sub-score |
|---|---|
| P/E | 3.2 |
| P/S | 7.1 |
| EV/EBITDA | 0.0 |
| Analyst target | 3.0 |
APLS · Why this verdict
Why Apellis Pharmaceuticals (APLS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue concentration in a single commercial drug means any adverse event, label change, pricing pressure, or competitive approval could materially impair the entire revenue base with no diversified product line to absorb the shock. Bear case | A second commercial product or pipeline approval contributes more than 15% of quarterly revenue within 18 months, beginning to reduce single-product dependence. | →Stable |
| CounterA wide economic moat can persist from a single dominant therapy with strong real-world evidence and established reimbursement; concentration risk only becomes catastrophic if the product faces an unforeseen regulatory or clinical setback. | ||
Revenue expanded 61% year-over-year, placing the company among the fastest-growing names in its peer group, and a wide economic moat suggests the growth has structural rather than purely cyclical roots. Growth breakdown | Revenue growth remains above 30% year-over-year for the next two fiscal quarters, confirming that demand expansion is holding as the commercial base matures. | →Stable |
| CounterRevenue is overwhelmingly concentrated in a single product; any clinical safety signal, label restriction, or competitive approval would simultaneously collapse both the growth rate and the moat argument, leaving no diversified revenue base to absorb the impact. | ||
Despite strong reported profits, free cash flow is negative at -48% of net income, meaning the business is not converting earnings into cash and may require external financing to sustain its investment program. Quality breakdown | Free cash flow turns positive and the FCF-to-net-income ratio rises above 0% for two consecutive quarters, signaling the business can fund itself from operations. | →Stable |
| CounterFor a commercial-stage biopharmaceutical investing heavily behind a recently launched product, negative free cash flow at this phase can reflect deliberate growth spending rather than structural impairment; if the revenue trajectory holds, cash conversion may normalize as launch investment decelerates. | ||
Three of the last four reported quarters produced positive earnings surprises — most recently beating by over 141% — with an average quarterly surprise of roughly 57%, a pattern suggesting the company consistently delivers above market expectations. Earnings | The next two quarterly prints both exceed consensus estimates, extending the beat record to five out of six quarters. | →Stable |
| CounterThe quarter immediately preceding the most recent result was a miss of -19.4%, showing the beat pattern is not guaranteed; high implied volatility near 120% indicates the market prices in large swings around each print, meaning a single negative surprise could produce an outsized price decline. | ||
Revenue concentration in a single commercial drug means any adverse event, label change, pricing pressure, or competitive approval could materially impair the entire revenue base with no diversified product line to absorb the shock.
→StableBear case
- Expectation
- A second commercial product or pipeline approval contributes more than 15% of quarterly revenue within 18 months, beginning to reduce single-product dependence.
CounterA wide economic moat can persist from a single dominant therapy with strong real-world evidence and established reimbursement; concentration risk only becomes catastrophic if the product faces an unforeseen regulatory or clinical setback.
Revenue expanded 61% year-over-year, placing the company among the fastest-growing names in its peer group, and a wide economic moat suggests the growth has structural rather than purely cyclical roots.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 30% year-over-year for the next two fiscal quarters, confirming that demand expansion is holding as the commercial base matures.
CounterRevenue is overwhelmingly concentrated in a single product; any clinical safety signal, label restriction, or competitive approval would simultaneously collapse both the growth rate and the moat argument, leaving no diversified revenue base to absorb the impact.
Despite strong reported profits, free cash flow is negative at -48% of net income, meaning the business is not converting earnings into cash and may require external financing to sustain its investment program.
→StableQuality breakdown
- Expectation
- Free cash flow turns positive and the FCF-to-net-income ratio rises above 0% for two consecutive quarters, signaling the business can fund itself from operations.
CounterFor a commercial-stage biopharmaceutical investing heavily behind a recently launched product, negative free cash flow at this phase can reflect deliberate growth spending rather than structural impairment; if the revenue trajectory holds, cash conversion may normalize as launch investment decelerates.
Three of the last four reported quarters produced positive earnings surprises — most recently beating by over 141% — with an average quarterly surprise of roughly 57%, a pattern suggesting the company consistently delivers above market expectations.
→StableEarnings
- Expectation
- The next two quarterly prints both exceed consensus estimates, extending the beat record to five out of six quarters.
CounterThe quarter immediately preceding the most recent result was a miss of -19.4%, showing the beat pattern is not guaranteed; high implied volatility near 120% indicates the market prices in large swings around each print, meaning a single negative surprise could produce an outsized price decline.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Strong 61% revenue growth and a wide economic moat establish a compelling long-term case, but negative free cash flow relative to reported profits, heavy reliance on a single commercial drug, and a stock already trading above its near-term resistance target make the current setup unfavorable for new capital despite the fundamental quality of the underlying franchise.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 7.3 |
| Gross margin | 8.9 |
| Op margin | 3.9 |
| Net margin | 6.0 |
| Current ratio | 9.4 |
| FCF quality | 0.0 |
| Moat | 7.5 |
| Piotroski F | 7.8 |
- ▸Excellent ROE: 46%
- ▸Earnings quality RED FLAG: -48% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 61% YoY
Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 10.0 |
| vol acceleration | 5.5 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 5.0 |
Insider
5.0/10data confidence 50%Peer rank
5.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.4 |
| quality rank | 7.9 |
| growth rank | 7.3 |
- ▸Superior ROE vs peers
Technical
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.6 |
| support resistance | 3.2 |
| 52w position | 9.9 |
Risk (lower is worse)
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.7 |
| days to cover | 9.8 |
| volatility | 10.0 |
| put call | 2.3 |
| implied vol | 2.0 |
| debt equity | 4.7 |
- ▸Elevated put/call: 1.65
- ▸High IV: 68%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.2/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:5.2>=4.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:27d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.9=NEGATIVE
Warning (2)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.88
Upside
-13.2%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 27d with 3/4 beat streak
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 5.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.9=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.88 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Catalyst at 7.2, and Quality at 6.8; the weakest are Value at 3.2, Insider at 5.0, and Sentiment at 5.0. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -0.88 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Growth Economic Moat
Trip ifRevenue growth falls below 20% year-over-year for 2 consecutive quarters.
- P2Negative Fcf Cash Burn Risk
Trip ifFree cash flow to net income ratio rises above 0% for 2 consecutive quarters, confirming positive cash conversion.
- P3Single Product Concentration Fragility
Trip ifA second commercial product contributes more than 15% of total quarterly revenue for 2 consecutive quarters, reducing single-product concentration.
- P4Earnings Beat Momentum
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, breaking the positive beat cadence.